L.C. Coates, MB ChB, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK.
J Rheumatol. 2022 Jun;49(6 Suppl 1):52-54. doi: 10.3899/jrheum.211331. Epub 2022 Mar 15.
Since its inception, one of the central missions of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has been the development of treatment recommendations for patients with psoriatic arthritis (PsA). The initial guidelines, developed in 2009, were updated in 2015. Because of the abundance of new data concerning the therapeutic approach to PsA, GRAPPA members have been working throughout 2020-2021 to once again update the recommendations. At the GRAPPA 2021 annual meeting, the full committee presented proposals from each of the treatment domain groups, including the comorbidities and related conditions groups, based on previous systematic literature reviews. Overarching principles and summary evidence tables were presented, including results from a GRAPPA membership survey of patients and clinicians to assess levels of agreement. A draft of the figure for the treatment recommendations was presented and discussed with the wider membership.
自成立以来，银屑病和银屑病关节炎研究与评估组织（GRAPPA）的核心任务之一就是为银屑病关节炎（PsA）患者制定治疗建议。最初的指南于 2009 年制定，并于 2015 年更新。由于有关治疗银屑病关节炎的新数据大量增加，GRAPPA 成员在 2020-2021 年期间一直在努力再次更新建议。在 GRAPPA 2021 年年会上，全体委员会根据之前的系统文献回顾，展示了来自每个治疗领域小组的提案，包括合并症和相关疾病小组。提出了总体原则和总结证据表，包括 GRAPPA 成员对患者和临床医生进行的调查结果，以评估其一致性水平。还展示并与更广泛的成员讨论了治疗建议的图表草案。
